Stakeholders' Views of Integrating Universal Tumour Screening and Genetic Testing for Colorectal and Endometrial Cancer into Routine Oncology

Overview

Journal Eur J Hum Genet

Specialty Genetics

Date 2021 Apr 3

PMID 33811254

Citations 6

Authors

Rosie OShea

Nicole M Rankin

Maira Kentwell

Margaret Gleeson

Katherine M Tucker

Heather Hampel

Natalie Taylor

Sarah Lewis

Affiliations

Soon will be listed here.

Abstract

Mainstream genetic testing in routine oncology care requires implementation research to inform intervention design. In Australia, funding is available for oncology health professionals (OHP) to organise genetic testing (GT) for eligible colorectal and endometrial cancer patients as part of their routine care. To assess the health system ability to incorporate this practice change, we conducted an implementation survey using the Consolidated Framework for Implementation Research (CFIR). The online survey was available from April to September 2020 to OHP and genetic health professional (GHP). In total, 198 respondents attempted the survey, with 158 completed and 27 partial responses: 26% were GHP, 66% OHP and 8% pathologists. Of all responders, 50% were female, mainly practicing in public hospital settings (57%) in an urban location (80%) and with an 18-60 years plus age range. The majority of respondents saw the relative advantage of aligning GT to abnormal universal tumour screening (UTS) results, with 77% of GHP and 78% of OHP agreeing it would streamline care for patients. There was disagreement across healthcare professional groups about knowledge and self-efficacy, with 45% of GHP not viewing oncologists as 'feeling confident' to use genetic test results for treatment management decisions, while 62% of OHP felt confident in their ability. Both OHP and GHP's indicated embedding a genetic counsellor in oncology or having a genetics point of contact to support integrating of GT through UTS as favourable interventions. Implementation research findings allow for the design of targeted interventions and a model for GT integration into oncology.

Citing Articles

Consumer-oriented (patient and family) outcomes from nursing in genomics: a scoping review of the literature (2012-2022).

Keels J, Thomas J, Calzone K, Badzek L, Dewell S, Murthy V Front Genet. 2024; 15:1481948.

PMID: 39678377 PMC: 11638212. DOI: 10.3389/fgene.2024.1481948.

BRCA2, PALB2, RECQL4 Germline Pathogenic Variants, and Somatic TP53 Mutation in Triple Metachronous Malignancies: A Case Report and Literature Review.

Liu Y, Yang H, Fu X, Zhong L, Xu P, Fang F Int Med Case Rep J. 2024; 17:23-29.

PMID: 38223534 PMC: 10788051. DOI: 10.2147/IMCRJ.S440132.

A mainstreaming oncogenomics model: improving the identification of Lynch syndrome.

OShea R, Crook A, Jacobs C, Kentwell M, Gleeson M, Tucker K Front Oncol. 2023; 13:1140135.

PMID: 37305562 PMC: 10256118. DOI: 10.3389/fonc.2023.1140135.

Heterogeneity in the psychosocial and behavioral responses associated with a diagnosis of suspected Lynch syndrome in women with endometrial cancer.

Jonnagadla S, Joseland S, Saya S, Den Elzen N, Isbister J, Winship I Hered Cancer Clin Pract. 2022; 20(1):27.

PMID: 35840994 PMC: 9284782. DOI: 10.1186/s13053-022-00233-1.

Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.

Ramsey M, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, Chen H Fam Cancer. 2022; 22(1):91-97.

PMID: 35713757 PMC: 9204376. DOI: 10.1007/s10689-022-00300-5.

References

Uyar D, Neary J, Monroe A, Nugent M, Simpson P, Geurts J . Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer. Gynecol Oncol. 2018; 149(3):565-569. DOI: 10.1016/j.ygyno.2018.03.059. View

Mascarenhas L, Shanley S, Mitchell G, Spurdle A, Macrae F, Pachter N . Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providers. Asia Pac J Clin Oncol. 2018; 14(6):417-425. DOI: 10.1111/ajco.13076. View

Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M . Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care. Fam Cancer. 2019; 18(3):293-301. PMC: 6560008. DOI: 10.1007/s10689-019-00122-y. View

Hegde M, Ferber M, Mao R, Samowitz W, Ganguly A . ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med. 2013; 16(1):101-16. DOI: 10.1038/gim.2013.166. View

Ring K, Bruegl A, Allen B, Elkin E, Singh N, Hartman A . Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol. 2016; 29(11):1381-1389. PMC: 5541389. DOI: 10.1038/modpathol.2016.135. View

Syngal S, Fox E, Eng C, Kolodner R, Garber J . Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet. 2000; 37(9):641-5. PMC: 1734690. DOI: 10.1136/jmg.37.9.641. View

Chalabi M, Fanchi L, Dijkstra K, van den Berg J, Aalbers A, Sikorska K . Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020; 26(4):566-576. DOI: 10.1038/s41591-020-0805-8. View

OShea R, Rankin N, Kentwell M, Gleeson M, Salmon L, Tucker K . How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens. Genet Med. 2020; 22(9):1507-1516. DOI: 10.1038/s41436-020-0838-x. View

Palter V, Baker N, Pollett A, Daly C, Facey M, Rotenberg C . Learning by Example: An International Perspective on Reflex-Testing for Lynch Syndrome. Ann Surg Oncol. 2018; 26(2):425-436. DOI: 10.1245/s10434-018-6809-7. View

10.

Rana H, Kipnis L, Hehir K, Cronin A, Jaung T, Stokes S . Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecol Oncol. 2020; 160(2):457-463. DOI: 10.1016/j.ygyno.2020.11.003. View

11.

Schneider J, Davis J, Kauffman T, Reiss J, McGinley C, Arnold K . Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genet Med. 2015; 18(2):152-61. PMC: 4608844. DOI: 10.1038/gim.2015.43. View

12.

Norquist B, Harrell M, Brady M, Walsh T, Lee M, Gulsuner S . Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016; 2(4):482-90. PMC: 4845939. DOI: 10.1001/jamaoncol.2015.5495. View

13.

Win A, Young J, Lindor N, Tucker K, Ahnen D, Young G . Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012; 30(9):958-64. PMC: 3341109. DOI: 10.1200/JCO.2011.39.5590. View

14.

Bray F, Ferlay J, Laversanne M, Brewster D, Gombe Mbalawa C, Kohler B . Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015; 137(9):2060-71. DOI: 10.1002/ijc.29670. View

15.

Monahan K, Bradshaw N, Dolwani S, DeSouza B, Dunlop M, East J . Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2019; 69(3):411-444. PMC: 7034349. DOI: 10.1136/gutjnl-2019-319915. View

16.

Stoffel E, Mangu P, Gruber S, Hamilton S, Kalady M, Lau M . Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2014; 33(2):209-17. PMC: 5321096. DOI: 10.1200/JCO.2014.58.1322. View

17.

Vasen H, Abdirahman M, Brohet R, Langers A, Kleibeuker J, van Kouwen M . One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010; 138(7):2300-6. DOI: 10.1053/j.gastro.2010.02.053. View

18.

Beamer L, Grant M, Espenschied C, Blazer K, Hampel H, Weitzel J . Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol. 2012; 30(10):1058-63. PMC: 3341150. DOI: 10.1200/JCO.2011.38.4719. View

19.

West K, Burke W, Korngiebel D . Identifying "ownership" through role descriptions to support implementing universal colorectal cancer tumor screening for Lynch syndrome. Genet Med. 2017; 19(11):1236-1244. PMC: 5671377. DOI: 10.1038/gim.2017.39. View

20.

Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C . Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23):2207-2218. DOI: 10.1056/NEJMoa2017699. View